S M Bristow1, G D Gamble1, A Pasch2, W C O'Neill3, A Stewart1, A M Horne1, I R Reid4,5,6. 1. University of Auckland, Auckland, New Zealand. 2. Department of Clinical Chemistry, University Hospital Bern, Inselspital, Bern, Switzerland. 3. Renal Division, School of Medicine, Emory University, Atlanta, GA, USA. 4. University of Auckland, Auckland, New Zealand. i.reid@auckland.ac.nz. 5. Department of Endocrinology, Auckland District Health Board, Auckland, New Zealand. i.reid@auckland.ac.nz. 6. Faculty of Medical and Health Sciences, University of Auckland, Private Bag 92019, Auckland, New Zealand. i.reid@auckland.ac.nz.
Abstract
SUMMARY:Calcium supplements have been associated with increased cardiovascular risk, but the mechanism is unknown. We investigated the effects of calcium supplements on the propensity of serum to calcify, based on the transition time of primary to secondary calciprotein particles (T50). Changes in serum calcium were related to changes in T50. INTRODUCTION:Calcium supplements have been associated with increased cardiovascular risk; however, it is unknown whether this is related to an increase in vascular calcification. METHODS: We investigated the acute and 3-month effects of calcium supplements on the propensity of serum to calcify, based on the transition time of primary to secondary calciprotein particles (T50), and on three possible regulators of calcification: fetuin-A, pyrophosphate and fibroblast growth factor-23 (FGF23). We randomized 41 postmenopausal women to 1 g/day ofcalcium as carbonate, or to a placebo containing no calcium. Measurements were performed at baseline and then 4 and 8 h after their first dose, and after 3 months of supplementation. Fetuin-A, pyrophosphate and FGF23 were measured in the first 10 participants allocated to calcium carbonate and placebo who completed the study. RESULTS: T50 declined in both groups, the changes tending to be greater in the calcium group. Pyrophosphate declined from baseline in the placebo group at 4 h and was different from the calcium group at this time point (p = 0.04). There were no other significant between-groups differences. The changes in serum total calcium from baseline were significantly related to changes in T50 at 4 h (r = -0.32, p = 0.05) and 8 h (r = -0.39, p = 0.01), to fetuin-A at 3 months (r = 0.57, p = 0.01) and to pyrophosphate at 4 h (r = 0.61, p = 0.02). CONCLUSIONS: These correlative findings suggest that serum calcium concentrations modulate the propensity of serum to calcify (T50), and possibly produce counter-regulatory changes in pyrophosphate and fetuin-A. This provides a possible mechanism by which calcium supplements might influence vascular calcification.
RCT Entities:
SUMMARY:Calcium supplements have been associated with increased cardiovascular risk, but the mechanism is unknown. We investigated the effects of calcium supplements on the propensity of serum to calcify, based on the transition time of primary to secondary calciprotein particles (T50). Changes in serum calcium were related to changes in T50. INTRODUCTION:Calcium supplements have been associated with increased cardiovascular risk; however, it is unknown whether this is related to an increase in vascular calcification. METHODS: We investigated the acute and 3-month effects of calcium supplements on the propensity of serum to calcify, based on the transition time of primary to secondary calciprotein particles (T50), and on three possible regulators of calcification: fetuin-A, pyrophosphate and fibroblast growth factor-23 (FGF23). We randomized 41 postmenopausal women to 1 g/day of calcium as carbonate, or to a placebo containing no calcium. Measurements were performed at baseline and then 4 and 8 h after their first dose, and after 3 months of supplementation. Fetuin-A, pyrophosphate and FGF23 were measured in the first 10 participants allocated to calcium carbonate and placebo who completed the study. RESULTS: T50 declined in both groups, the changes tending to be greater in the calcium group. Pyrophosphate declined from baseline in the placebo group at 4 h and was different from the calcium group at this time point (p = 0.04). There were no other significant between-groups differences. The changes in serum total calcium from baseline were significantly related to changes in T50 at 4 h (r = -0.32, p = 0.05) and 8 h (r = -0.39, p = 0.01), to fetuin-A at 3 months (r = 0.57, p = 0.01) and to pyrophosphate at 4 h (r = 0.61, p = 0.02). CONCLUSIONS: These correlative findings suggest that serum calcium concentrations modulate the propensity of serum to calcify (T50), and possibly produce counter-regulatory changes in pyrophosphate and fetuin-A. This provides a possible mechanism by which calcium supplements might influence vascular calcification.
Authors: Andreas Pasch; Stefan Farese; Steffen Gräber; Johanna Wald; Walter Richtering; Jürgen Floege; Willi Jahnen-Dechent Journal: J Am Soc Nephrol Date: 2012-09-06 Impact factor: 10.121
Authors: Y Nishida; Y Taketani; H Yamanaka-Okumura; F Imamura; A Taniguchi; T Sato; E Shuto; K Nashiki; H Arai; H Yamamoto; E Takeda Journal: Kidney Int Date: 2006-10-25 Impact factor: 10.612
Authors: Rajnish Mehrotra; Ralf Westenfeld; Peter Christenson; Matthew Budoff; Eli Ipp; Junichiro Takasu; Ajay Gupta; Keith Norris; Markus Ketteler; Sharon Adler Journal: Kidney Int Date: 2005-03 Impact factor: 10.612
Authors: Mark J Bolland; Tom K M Wang; Niels C van Pelt; Anne M Horne; Barbara H Mason; Ruth W Ames; Andrew B Grey; Peter N Ruygrok; Greg D Gamble; Ian R Reid Journal: J Bone Miner Res Date: 2010-03 Impact factor: 6.741
Authors: María E Rodriguez-Ortiz; Ignacio Lopez; Juan R Muñoz-Castañeda; Julio M Martinez-Moreno; Alan Peralta Ramírez; Carmen Pineda; Antonio Canalejo; Philippe Jaeger; Escolastico Aguilera-Tejero; Mariano Rodriguez; Arnold Felsenfeld; Yolanda Almaden Journal: J Am Soc Nephrol Date: 2012-05-10 Impact factor: 10.121
Authors: So Young Bu; Mi Ja Choi; Da Seul Choi; You-Mi Jung; In-Sil Jang; Narae Yang; Kirang Kim; Clara Yongjoo Park Journal: Nutr Res Pract Date: 2022-02-14 Impact factor: 1.992